Kenneth A. Foon
#133,589
Most Influential Person Now
Kenneth A. Foon's AcademicInfluence.com Rankings
Kenneth A. Foonmedical Degrees
Medical
#2272
World Rank
#2683
Historical Rank
Oncology
#131
World Rank
#135
Historical Rank

Kenneth A. Foonphilosophy Degrees
Philosophy
#6629
World Rank
#9693
Historical Rank
Logic
#3771
World Rank
#4979
Historical Rank

Download Badge
Medical Philosophy
Kenneth A. Foon's Degrees
- Doctorate Medicine University of California, San Francisco
- PhD Radiation Oncology University of California, San Francisco
Why Is Kenneth A. Foon Influential?
(Suggest an Edit or Addition)Kenneth A. Foon's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. (1998) (1726)
- IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. (1997) (1245)
- Immunologic classification of leukemia and lymphoma. (1986) (790)
- Flow cytometric immunophenotyping for hematologic neoplasms. (2008) (599)
- IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma (1997) (572)
- Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. (1985) (538)
- Surface markers on leukemia and lymphoma cells: recent advances. (1982) (433)
- Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working group (1988) (399)
- Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. (2004) (322)
- Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. (1984) (285)
- Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. (1984) (264)
- Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. (1997) (258)
- Increased Frequency and Suppression by Regulatory T Cells in Patients with Acute Myelogenous Leukemia (2009) (255)
- Chronic lymphocytic leukemia: new insights into biology and therapy. (1990) (249)
- Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. (2004) (224)
- Biological response modifiers: the new immunotherapy. (1989) (212)
- Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration. (1984) (193)
- Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. (2009) (190)
- IDEC-C 2 B 8 ( Rituximab ) Anti-CD 20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin ’ s Lymphoma (1997) (186)
- T gamma-lymphoproliferative disease and related disorders in humans and experimental animals: a review of the clinical, cellular, and functional characteristics (1984) (182)
- Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. (1984) (178)
- Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. (1999) (169)
- A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. (1982) (157)
- Chronic lymphocytic leukemia. Recent advances in biology and treatment. (1985) (153)
- Response to 2'-deoxycoformycin after failure of interferon-alpha in nonsplenectomized patients with hairy cell leukemia. (1986) (151)
- Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. (1995) (151)
- Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia. Therapeutic and immunologic results. (1986) (151)
- The role of recombinant interferon alfa‐2a in the therapy of cutaneous t‐cell lymphomas (1986) (146)
- Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. (2000) (138)
- Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. (1997) (136)
- Intensive chemotherapy for acute myelogenous leukemia. (1981) (129)
- Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody. (1986) (118)
- The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. (2006) (118)
- Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia. (1981) (118)
- Immunologic classification of lymphocytic leukemias based on monoclonal antibody-defined cell surface antigens. (1982) (112)
- Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia. (1985) (109)
- Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients (2017) (104)
- Phase II Trial of Short-Course CHOP-R Followed by 90Y-ibritumomab Tiuxetan and Extended Rituximab in Previously Untreated Follicular Lymphoma (2008) (103)
- Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonic antigen. (1990) (98)
- Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. (1998) (97)
- Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors (2009) (97)
- Interferon‐α therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia (1992) (90)
- Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain (1998) (89)
- Kinetic model for the biodistribution of an 111In-labeled monoclonal antibody in humans. (1987) (85)
- U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: medical indications. (1997) (84)
- Type 1‐polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia (2008) (83)
- Effect of antibody dose on the imaging and biodistribution of indium-111 9.2.27 anti-melanoma monoclonal antibody. (1988) (82)
- Alpha interferon in the treatment of hematologic malignancies. (1986) (82)
- Controversies in the therapy of acute myelogenous leukemia. (1982) (79)
- Monoclonal antibodies reactive with acute myelogenous leukemia cells. (1981) (78)
- Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. (1988) (78)
- Determination of the optimal human cell lines for development of human hybridomas. (1983) (77)
- Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. (2017) (77)
- Selective antitumor effect on L10 hepatocarcinoma cells of a potent immunoconjugate composed of the A chain of abrin and a monoclonal antibody to a hepatoma-associated antigen. (1984) (76)
- Guinea pig line 10 hepatocarcinoma model: characterization of monoclonal antibody and in vivo effect of unconjugated antibody and antibody conjugated to diphtheria toxin A chain. (1983) (76)
- Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma. (1987) (72)
- T65 antigen modulation in a phase I monoclonal antibody trial with chronic lymphocytic leukemia patients. (1984) (72)
- Genetic Relatedness of Lymphoid Malignancies: Transformation of Chronic Lymphocytic Leukemia as a Model (1993) (68)
- The antigenic characteristics of hematopoietic stem cells. (1981) (68)
- Biology of chronic lymphocytic leukemia. (1987) (65)
- Induction of antitumor immunity by an anti-idiotype antibody mimicking carcinoembryonic antigen. (1997) (65)
- PROLONGED SURVIVAL IN ACUTE MYELOGENOUS LEUKAEMIA WITHOUT MAINTENANCE CHEMOTHERAPY (1984) (64)
- Anti-idiotype vaccine against cancer. (2000) (62)
- A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study (2014) (57)
- Recombinant leukocyte A interferon in advanced breast cancer. Results of a phase II efficacy trial. (1983) (57)
- Atypical tumor lysis syndrome in a patient with T cell lymphoma treated with recombinant leukocyte interferon. (1984) (57)
- Dual B and T markers in acute and chronic lymphocytic leukemia. (1980) (56)
- Increased growth of eyelashes in a patient given leukocyte A interferon. (1984) (56)
- 2-Chlorodeoxyadenosine-Induced Complete Remissions in Langerhans-Cell Histiocytosis (1994) (55)
- Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody. (1998) (55)
- Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. (2012) (54)
- Intratumor localization of monoclonal antibody in patients with melanoma treated with antibody to a 250,000-dalton melanoma-associated antigen. (1985) (51)
- Localization of 111In- and 125I-labeled monoclonal antibody in guinea pigs bearing line 10 hepatocarcinoma tumors. (1983) (49)
- Recent advances in the immunologic classification of leukemia. (1986) (49)
- Acute myelogenous leukemia: morphologic classification and response to therapy. (1979) (49)
- Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2. (1997) (49)
- Fate of gamma-interferon-activated killer blood monocytes adoptively transferred into the abdominal cavity of patients with peritoneal carcinomatosis. (1987) (48)
- A phase I trial of recombinant gamma interferon in patients with cancer (2004) (47)
- Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2. (1998) (46)
- Interferon-alpha therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia. (1992) (46)
- IMAGING OF T-CELL LYMPHOMA BY RADIOLABELLED MONOCLONAL ANTIBODY (1984) (46)
- Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression. (2001) (45)
- A prospective randomized trial of alpha 2B-interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma. (1988) (45)
- T gamma-lymphoproliferative disease and related disorders in humans and experimental animals: a review of the clinical, cellular, and functional characteristics. (1984) (44)
- Counterpoint. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine (2000) (44)
- Biodistribution, pharmacokinetic, and imaging studies with 186Re-labeled NR-LU-10 whole antibody in LS174T colonic tumor-bearing mice. (1990) (44)
- Approved monoclonal antibodies for cancer therapy. (2008) (44)
- Lymphokines, monoclonal antibodies, and other biological response modifiers in the treatment of cancer (1984) (44)
- The role of immunotherapy in acute myelogenous leukemia. (1983) (43)
- Immune markers in hematologic malignancies. (1991) (42)
- Dendritic Cells Pulsed with an Anti-Idiotype Antibody Mimicking Carcinoembryonic Antigen (CEA) Can Reverse Immunological Tolerance to CEA and Induce Antitumor Immunity in CEA Transgenic Mice (2004) (41)
- Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant (2008) (41)
- Serotonin-induced production of a monocyte chemotactic factor by human peripheral blood leukocytes. (1976) (41)
- Colorectal cancer as a model for immunotherapy. (1999) (40)
- Therapy of acute myelogenous leukemia. (1992) (39)
- Are solid tumor anti-idiotype vaccines ready for prime time? Commentary re: U. Wagner et al., Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin. Cancer Res., 7: 1154-1162, 2001. (2001) (39)
- Relationship of the clinical response and binding of recombinant interferon alpha in patients with lymphoproliferative diseases. (1986) (38)
- Immunologic classification of acute lymphoblastic leukemia. Implications for normal lymphoid differentiation. (1980) (38)
- Approved monoclonal antibodies for cancer therapy (2008) (37)
- Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restricted T-cell antigen. (1995) (37)
- Guinea pig line 10 hepatocarcinoma model for monoclonal antibody serotherapy: in vivo localization of a monoclonal antibody in normal and malignant tissues. (1983) (37)
- Interferon gamma augments Lym-1-dependent, granulocyte-mediated tumor cell lysis. (1990) (37)
- Interferon therapy of non‐Hodgkin's lymphoma (1987) (36)
- Immunologic defects in young male patients with hepatitis-associated aplastic anemia. (1984) (35)
- The anti-idiotype vaccines for immunotherapy. (2001) (34)
- Murine monoclonal anti‐idiotypic antibody as a surrogate antigen for human Her‐2/neu (2001) (34)
- Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules. (2005) (34)
- Anti-idiotype antibody vaccine therapies of cancer. (2002) (34)
- Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity. (2003) (33)
- Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in Follicular Lymphoma: Results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) Investigation Using Individual Data from 5,453 Patients on 13 Clinical Trials (2017) (33)
- Evening administration of alpha interferon. (1985) (32)
- Production of large quantities of human immunoglobulin in the ascites of athymic mice: implications for the development of anti-human idiotype monoclonal antibodies. (1984) (31)
- Therapy of acute myelogenous leukemia. (1992) (31)
- Anti-idiotype antibody vaccine therapy for cancer (2002) (30)
- Recombinant interferon alfa‐2a, an active agent in advanced cutaneous t‐cell lymphomas (1987) (30)
- Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen (2003) (29)
- Construction and characterization of DNA vaccines encoding the single-chain variable fragment of the anti-idiotype antibody 1A7 mimicking the tumor-associated antigen disialoganglioside GD2 (2000) (29)
- Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. (2007) (29)
- Heterogeneity in a lymphoid tumor: coexpression of T and B surface markers. (1982) (28)
- Immunolymphoscintigraphy and the dose dependence of 111In-labeled T101 monoclonal antibody in patients with cutaneous T-cell lymphoma. (1987) (28)
- Alpha interferon treatment of low-grade B-cell non-Hodgkin's lymphomas, cutaneous T-cell lymphomas, and chronic lymphocytic leukemia. (1986) (28)
- Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in FL from 5,225 Patients on 13 Clinical Trials. (2021) (27)
- Leukemia of T-helper lymphocytes: clinical and functional features. (1981) (27)
- Human alveolar macrophages express Ia-like antigens. (1981) (27)
- Induction of human breast cancer-specific antibody responses in cynomolgus monkeys by a murine monoclonal anti-idiotype antibody. (1995) (27)
- A preliminary Phase I trial of partially purified interferon-gamma in patients with cancer. (1984) (27)
- A phase I evaluation of poly(I,C)-LC in cancer patients. (1985) (26)
- Adjuvant immunotherapy for melanoma and colorectal cancers. (2001) (26)
- CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice (2006) (26)
- Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma (2015) (26)
- Antibody-dependent, cell-mediated cytotoxicity by an anti-class II murine monoclonal antibody: effects of recombinant interleukin 2 on human effector cell lysis of human B-cell tumors. (1990) (25)
- Detection of two distinct malignant B cell clones in a single patient using anti-idiotype monoclonal antibodies and immunoglobulin gene rearrangement. (1985) (25)
- Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients. (2017) (25)
- Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias (2012) (25)
- Low- versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphoma. (1990) (24)
- Flow cytometry: recent advances in diagnosis and monitoring of leukemia. (1997) (24)
- Overview of monoclonal antibodies in the diagnosis and therapy of cancer. (1991) (24)
- Acute myelogenous leukemia heteroantisera. (1980) (24)
- Antigen mimicry by an anti-idiotypic antibody single chain variable fragment. (1998) (23)
- Anti-idiotype monoclonal antibodies as vaccines for human cancer. (1991) (23)
- Changing paradigms in the treatment of chronic lymphocytic leukemia (2010) (23)
- Use of the anti-idiotype breast cancer vaccine 11D10 in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer. (2003) (22)
- Clinical significance of monoclonal proteins in chronic lymphocytic leukemia. (1992) (22)
- The generation of monoclonal anti-idiotype antibodies to human B cell-derived leukemias and lymphomas. (1985) (22)
- Renal Cell Carcinoma Treated with Continuous‐Infusion Interleukin‐2 with Ex Vivo‐Activated Killer Cells (1992) (22)
- Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu (2007) (22)
- Tumor associated antigen (TAA) mimicry and immunotherapy of malignant diseases from anti-idiotypic antibodies to peptide mimics. (2001) (21)
- Posttransfusion hepatitis in acute myelogenous leukemia. Effect on survival. (1980) (21)
- Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients (2009) (20)
- Anti‐idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen (2006) (20)
- Biological and Hormonal Therapies of Cancer (1998) (20)
- Idiotypic antibody immunotherapy of cancer (1994) (20)
- Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL). (2017) (20)
- MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma. (2019) (19)
- Chronic leukemias: oncogenes, chromosomes, and advances in therapy. (1986) (19)
- Monoclonal antibody therapy in malignant melanoma: factors effecting in vivo localization. (1987) (18)
- Chronic lymphoid leukemias: Recent advances in biology and therapy (1995) (18)
- Recombinant alpha interferon in retreatment of two patients with pulmonary lymphoma. Dramatic responses with resolution of pulmonary complications. (1984) (18)
- Construction and characterization of a chimeric fusion protein consisting of an anti-idiotype antibody mimicking a breast cancer-associated antigen and the cytokine GM-CSF. (1999) (18)
- Biological therapy of cancer (2005) (18)
- Preclinical evaluation in nonhuman primates of an anti-idiotypic antibody that mimicks the carcinoembryonic antigen. (1995) (18)
- Novel Therapies for Aggressive B-Cell Lymphoma (2012) (18)
- Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells. (2010) (17)
- Current and future uses of recombinant interferon alpha in the treatment of low‐grade non‐Hodgkin's lymphoma (1987) (17)
- Immunomodulatory effects of poly(I,C)-LC in cancer patients. (1985) (17)
- Light chain disease associated with the hyperviscosity syndrome (1987) (17)
- Immunologic classification of childhood acute lymphocytic leukemia (1981) (17)
- Localization and imaging with radioiodine-labeled monoclonal antibodies in a xenogeneic tumor model for human B-cell lymphoma. (1988) (16)
- Anti-idiotype antibodies as potential therapeutic agents for human breast cancer. (1994) (16)
- Monoclonal Antibody Therapy of Cancer: Preclinical Models and Investigations in Humans (1986) (16)
- Phase II Trial of Abbreviated CHOP-Rituximab Followed by 90Y Ibritumomab Tiuxetan (Zevalin) and Rituximab in Patients with Previously-Untreated Follicular Non-Hodgkin Lymphoma (NHL). (2005) (15)
- Shared idiotype expression by chronic lymphocytic leukemia and B-cell lymphoma. (1990) (15)
- Antiidiotype (Ab2) Vaccine Therapy for Cutaneous T‐Cell Lymphoma a (1993) (15)
- Analysis of the systemic corticosteroid sensitivity of patients with primary open-angle glaucoma. (1977) (15)
- Acute myeloid leukaemia: recent advances in therapy. (1986) (15)
- Acute myelogenous leukemia: current status of therapy in adults. (1984) (14)
- Phase 1 Dose Escalation Study of TRU-016, An Anti-CD37 SMIP™ Protein In Relapsed and Refractory CLL (2010) (14)
- Demonstration of macrophage chemotactic factors in the aqueous humor during experimental immunogenic uveitis in rabbits (1976) (14)
- The B lineage transcription factor E2A regulates apoptosis in chronic lymphocytic leukemia (CLL) cells. (2011) (13)
- MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R2) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma (2016) (13)
- Alpha-interferon treatment of cutaneous T cell lymphoma and chronic lymphocytic leukemia. (1986) (12)
- Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: potential cure for an incurable disease (2007) (12)
- Monoclonal Antibody Therapy of Human Cancer (2012) (12)
- A trial of autologous plasma perfusion over protein A in patients with breast cancer. (1984) (12)
- Monoclonal antibody therapy of leukaemias and lymphomas (2005) (12)
- Monoclonal antibody therapies for lymphomas. (2000) (12)
- Generation of Her-2/neu vaccine utilizing idiotypic network cascade (2007) (12)
- Immunologic classification of lymphoma and lymphoid leukemia. (1987) (12)
- Idiotype vaccines in the clinic (1998) (12)
- Expression of Ia-like antigens in human erythroid progenitor cells as determined by monoclonal antibodies and heteroantiserum to Ia-like antigens. (1981) (11)
- Gemtuzumab ozogamicin as first‐line treatment in patients aged 70 years or older with acute myeloid leukemia (2010) (11)
- Unusual gastrointestinal complications of interleukin-2 therapy. (1991) (11)
- Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy. (2011) (11)
- Staging and therapy of chronic lymphocytic leukemia. (1987) (11)
- Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer. (2001) (11)
- Interferon therapy for lymphoproliferative disorders. (1988) (10)
- Is there a T-cell form of chronic lymphocytic leukemia? (1992) (10)
- Carcinoembryonic Antigen Transgenic Mouse Models for Immunotherapy and Development of Cancer Vaccines (2008) (10)
- Laboratory and clinical applications of monoclonal antibodies for leukemias and non-Hodkin's lymphoma (1989) (10)
- Human Antiglobulin Responses (2005) (10)
- A MONOCLONAL ANTIBODY RECOGNIZING HUMAN THY‐ 1: DISTRIBUTION ON HUMAN AND NON‐HUMAN PRIMATE HAEMATOPOIETIC CELLS (1984) (10)
- An antigen expressed by cells of the myelo‐monocytic lineage (1981) (9)
- Biologic response modifiers: therapeutic approaches to lymphoproliferative diseases. (1992) (9)
- Ex vivo activated monocytes and adoptive immunotherapy trials in colon cancer patients. (1986) (9)
- Phase II study of short course CHOP-rituximab (R) followed by ibritumomab tiuxetan (IT) as first-line treatment for follicular lymphoma (FL) (2007) (9)
- Immunotherapy for colorectal cancer (2001) (9)
- Detection of differentiation antigens by use of monoclonal antibodies. (1981) (9)
- Monoclonal antibodies in the treatment of cancer: Preliminary observations and future prospects (1984) (8)
- Monoclonal antibodies to human colorectal tumor-associated antigens: improved elicitation and subclass restriction. (1984) (8)
- Therapeutic options in advanced cutaneous T cell lymphomas: a role for interferon alfa-2a (Roferon-A). (1985) (8)
- An antithymocyte serum noncytotoxic to myeloid progenitor cells: candidate serum for prevention of graft-versus-host disease in bone marrow transplantation. (1980) (8)
- Preclinical and Clinical Evaluation of a Monoclonal Antibody to a Human Melanoma-Associated Antigen (1985) (8)
- Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706 (2005) (8)
- The treatment of cancer patients with human lymphoblastoid interferon (2004) (8)
- The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas (2007) (8)
- NK cells in cancer immunotherapy: three decades of discovery. (2006) (7)
- Cancer Vaccines: Activating the Immune System to Fight Cancer (2008) (7)
- Optimal strategies for developing human-human monoclonal antibodies. (1986) (7)
- A Randomized Controlled Trial of Spiritually-Focused Meditation In Patients Newly Diagnosed with Acute Leukemia. (2010) (7)
- Treatment of acute myelogenous leukemia in older patients. (1981) (7)
- Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low‐grade follicular lymphomas (2002) (6)
- Interferon use in solid tumors. (1998) (6)
- Monoclonal antibody characterization of plasmacytoma cells associated with T lymphocytes with a suppressor phenotype. (1982) (6)
- Histiocytic lymphoma following resolution of sarcoidosis. (1981) (6)
- Monoclonal Antibody Therapy for Patients with Leukemia and Lymphoma (1985) (6)
- Improved imaging of metastatic melanoma with high dose 9. 2. 27 In-111 monoclonal antibody (1985) (5)
- Evaluation of alternative methodologies for the generation of murine monoclonal anti-idiotypic antibodies to human B cell leukemias and lymphomas. (1986) (5)
- Translational Research: Advancing Medical Science by Stimulating Interdisciplinary Research (2007) (5)
- Natural killer cells: from bench to cancer therapy (2006) (5)
- The immunological classification of leukaemia based on a rapid microcytotoxicity test. (1982) (5)
- Clinical transformation of chronic lymphocytic leukemia. (1988) (5)
- Sclerodactyly in a patient with mycosis fungoides. (1985) (4)
- Monoclonal antibody to human eosinophils recognizing 95 kD surface membrane antigen. (1983) (4)
- Clinical applications of monoclonal antibodies for patients with leukemia and lymphoma. (1986) (4)
- The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity. (1992) (4)
- Idiotype manipulation in disease management. (1995) (4)
- Laboratory and clinical applications of monoclonal antibodies for leukemias and non-Hodgkin's lymphomas. (1989) (4)
- Posttransfusion Hepatitis in Acute Myelogenous Leukemia-Reply (1981) (4)
- Two new monoclonal antibodies to human monocytes and granulocytes: isolation of membrane antigens and lack of effects of antibodies on leukocyte functions in vitro. (1984) (4)
- CLINICAL RESPONSE TO ANTI-IDIOTYPE MONOCLONAL ANTIBODY VACCINE THERAPY FOR PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (1993) (3)
- Mechanisms of Suppression Used by Regulatory T Cells in Patients Newly Diagnosed with Acute Myeloid Leukemia (2008) (3)
- ACTIVE IMMUNITY TO THE CARCINOEMBRYONIC ANTIGEN (CEA) IN PATIENTS TREATED WITH AN ANTI-IDIOTYPE MONOCLONAL ANTIBODY VACCINE (1994) (3)
- A Phase II Study of the Combination of FCR-Lite and Lenalidomide Followed By Lenalidomide Maintenance in Front-Line CLL: The FCR2 Regimen (2014) (3)
- Immunotherapy of gynecologic malignancies. (1990) (3)
- Immunologic approaches to the classification of lymphomas and lymphoid leukemias. (1988) (3)
- A Phase I Trial of Immune Interferon (1984) (3)
- Biotherapy of cancer with interleukin-2, colony-stimulating factors, and monoclonal antibodies. (1988) (3)
- Dendritic cells pulsed with an anti-idiotype antibody mimicking Her-2 induced protective antitumor immunity in mice transgenic for human Her-2 (2008) (2)
- MAGNIFY: A phase 3B, randomized trial of lenalidomide plus rituximab induction and maintenance therapy followed by lenalidomide single-agent versus rituximab maintenance in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL). (2014) (2)
- Early Clinical and Pharmacokinetic Results of Lower Dose Fludarabine and Cyclophosphamide, and High Dose Rituximab (FCR-Lite) for Patients with Untreated Chronic Lymphocytic Leukemia (CLL). (2006) (2)
- Localization of yttrium 90 ibritumomab tiuxetan (90Y IT) in patients with CD20 + non-Hodgkin's lymphoma (NHL) (2005) (2)
- Current status of interferon therapy in oncology. (1987) (2)
- Cellular Localization Pattern of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in a Patient with Low-Grade Non-Hodgkin’s Lymphoma (NHL). (2004) (2)
- Imaging results after CHOP-rituximab followed by 90Y ibritumomab tiuxetan and rituximab (R) in patients with previously-untreated follicular lymphoma (FL). (2006) (2)
- Anti-Idiotype Vaccines (2004) (2)
- Prognostic testing patterns in CLL pts treated in U.S. practices from the Connect CLL registry. (2015) (2)
- Immunolymphoscintigraphy with Indium-111 labeled T101 monoclonal antibody (1985) (2)
- Phase II Study of Short Course CHOP-Rituximab Followed by 90-Y Ibritumomab Tiuxetan as First-Line Treatment for Follicular Lymphoma: An Update and Extension of Preliminary Findings on Predictors of Relapse. (2008) (2)
- IDEC-C2B8: INITIAL PHASE II RESULTS IN PATIENTS WITH B-CELL LYMPHOMA (1994) (2)
- Therapeutic Anti-clonotypic Vaccines (1993) (2)
- The generation of stable human T-cell hybridomas which constitutively produce interleukin-2 and chemotactic factor. (1985) (2)
- Measurements of human anti murine antibodies in patients who received radiolabeled monoclonal antibodies (1986) (1)
- Advances of immunotherapy of cancer: monoclonal antibodies and interferon. (1988) (1)
- Daunorubicin or doxorubicin in acute myelogenous leukemia? (1988) (1)
- Immunity in CEA Transgenic Mice Immunological Tolerance to CEA and Induce Antitumor Mimicking Carcinoembryonic Antigen ( CEA ) Can Reverse Dendritic Cells Pulsed with an Anti-Idiotype Antibody (2004) (1)
- PS1253 MAGNIFY: PHASE IIIB INTERIM ANALYSIS OF INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA (2019) (1)
- Final Results of Lower Dose Fludarabine (F) and Cyclophosphamide (C), and High Dose Rituximab (R), (FCR-Lite) for Patients with Untreated Chronic Lymphocytic Leukemia (CLL). (2007) (1)
- Erratum: Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen (Immunology (2006) 118, (483-496)) (2006) (1)
- A randomized prospective trial of the benefit of postoperative radiotherapy in the treatment of single metastases to the brain (1998) (1)
- A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group (2019) (1)
- Dendritic cell based vaccines for immunotherapy of (2003) (1)
- Pharmacokinetics of In-111 T101 (anti-CD5) monoclonal antibody in patients with cutaneous T-cell lymphoma (1993) (1)
- Biological approaches to cancer therapy. (1987) (1)
- Clearly defined response criteria evaluating treatment of CLL patients in clinical research trials. (2010) (1)
- Immunoglobulin Heavy Chain (IgH) Gene Somatic Hypermutation Status Using Homoduplex-Separated RT-PCR Products. (2004) (1)
- Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders: BCL2 as a prognostic marker (2007) (1)
- Functional properties of subsets of T lymphocytes defined by specific antigens. (1981) (1)
- Increased frequency and suppressive function of CD4+ CD25high regulatory T-cells in acute myeloid leukemia patients (2007) (1)
- Imaging of cutaneous T cell lymphoma (CTCL) with In-111-T101 monoclonal antibody (1985) (1)
- Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy (2011) (1)
- Efficacy of Mitoxantrone and Etoposide in Patients with Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy. (2007) (1)
- Inadvertent overdose with lomustine (CCNU) followed by hematologic recovery. (1982) (1)
- The role of E2A in B cell chronic lymphocytic leukemia (2008) (1)
- Anti-Idiotype Antibody Vaccines for the Immunotherapy of Cancer (2006) (1)
- Clinical and immune responses in metastatic melanoma patients immunized with an anti-idiotype (anti-Id) monoclonal antibody (mAb) mimicking disialoganglioside gd21 (1999) (1)
- Clinical Aspects of Interferon Therapy in Human Cancer (1988) (0)
- Therapeutic Applications of Monoclonal Antibodies for Lymphoma and Leukemia (1988) (0)
- Anti-idiotypic Monoclonal Antibodies: Novel Approach to Immunotherapy (1994) (0)
- Considerations in the diagnosis and therapy of human T-cell lymphoma with monoclonal antibodies (1989) (0)
- Biotherapy with interferon in hematologic malignancies. (1987) (0)
- Interleukin-15 Upregulates the Expression of NK-Cell Activating Receptors and Concomitantly Increases the NK Cytotoxicity in Patients with Acute Myeloid Leukemia. (2007) (0)
- Erratum (2006) (0)
- Monoclonal Antibody Therapy for Hematologic Malignancies (2010) (0)
- Monoclonal antibody therapy of lymphomas and leukemia. (1988) (0)
- MAGNIFY: A randomized, phase 3b trial in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) investigating lenalidomide plus rituximab (R2) induction followed by maintenance R2 followed by lenalidomide versus R2 induction followed by rituximab (R) maintenance. (2015) (0)
- Targeted knockdown of the B lineage transcriptional activator E2A in B cell chronic lymphocytic leukemia (CLL) enhances lenalidomide sensitivity and regulates cellular proliferation (88.7) (2009) (0)
- Treatment of cutaneous T-cell lymphomas with biologic response modifiers: Recombinant leukocyte A interferon and T101 monoclonal antibody (1985) (0)
- encoding for multiple costimulatory molecules (CLL): enhanced immunogenicity of CLL cells via infection with vectors Potential approach to immunotherapy of chronic lymphocytic leukemia (2013) (0)
- Human Alveolar Macrophages Express (2005) (0)
- 8th Annual San Antonio Breast Cancer Symposium Biological therapy of cancer (1986) (0)
- The Role of Interleukin-15 on Natural Killer Cell Homeostasis and Activity in Patients with Acute Myeloid Leukemia (2008) (0)
- Antigenic characteristics of normal and malignant human hematopoietic cells. Potential use of antigenic differences in cell separation and marrow transplantation. (1979) (0)
- Clinical a nd I mmune R esponses i n R esected C olon C ancer Patients T reated W ith A nti-Idiotype M onoclonal A ntibody Vaccine T hat M imics t he C arcinoembryonic A ntigen (1999) (0)
- Up-regulation of natural killer (NK) cell activating receptors and increase in NK mediated cytotoxicity using interleukin-15 in patients with newly diagnosed acute myeloid leukemia (AML) (2008) (0)
- that is selectively expressed in B-lymphoid cells and B-CLL The PANE1 gene encodes a novel human minor histocompatibility antigen (2013) (0)
- Modification of B-CLL Cells Via Infection with a Replication-Defective MVA Virus Encoding Three Costimulatory Molecules: A Potential Approach to Tumor Cell Immunotherapy of B-CLL. (2004) (0)
- Nasopharyngeal Cervical cancer Hematological malignancies Hairy cell leukemia * Non-Hodgkin ' s lymphoma Low grade Intermediate and high grade Hodgkin ' s disease Cutaneous T-cell lymphoma Chronic lymphocytic leukemia Multiple myeloma Chronic myelogenous leukemia (2006) (0)
- Serotonin (5 hydroxytryptamine) induced lymphokine production from human peripheral blood lymphocytes (1975) (0)
- 259 Induction of anti-tumor immunity by an anti-idiotype antibody mimicking human HER2/Neu (2004) (0)
- Generation of alpha-Type-1 Polarized Dendritic Cells as a Potent Immunogen in Patients with Chronic Lymphocytic Leukemia. (2007) (0)
- Commentary (Grandis/Foon): Emerging Role of EGFR-Targeted Therapies and Radiation in Head and Neck Cancer (2004) (0)
- Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. (1982) (0)
- Biological therapies: Twenty-five years of progress in cancer therapy (2006) (0)
- Interferon therapy of hematologic malignancies. (1998) (0)
- Biological Approaches to the Therapy of Lymphoproliferative Diseases (1985) (0)
- Anti-ldiotype Antibodies: Novel Therapeutic Approach to Cancer Therapy (2020) (0)
- Results of a Multi-Center, Phase II Study of Elsamitrucin (SPI-28090) in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma (NHL). (2005) (0)
- Immunotherapy of Cancer Patients with Anti-Idiotype Vaccines (1997) (0)
- An administrative structure for integration of multimodality image implementation and tumor-metric analysis for early assessment of therapeutic response in cancer by Image Response Assessment Teams (IRAT) (2008) (0)
- CD4+ CD25high Regulatory T Cells in Newly Diagnosed Patients with Acute Myeloid Leukemia. (2007) (0)
- A monoclonal antibody recognizing human thy-1: distribution on normal and malignant hematopoietic cells. Abstr. (1981) (0)
- Lymphocytic leukemias: new insights into biology and therapy. (1992) (0)
- Vaccine Strategies for Colorectal Cancer (2002) (0)
- An Alternative Transcript of the PANE1 Gene Encodes a Minor Histocompatibility Antigen That Is Selectively Expressed in Resting CD19+ Cells and B-CLL. (2005) (0)
- P12 Immune responses in melanoma patients immunized with an anti-idiotype (Id) antibody mimicking GD2 (1999) (0)
- Methods and Compositions for the Treatment of Psoriasis (2017) (0)
- Chronic Lymphocytic Leukemia (2020) (0)
- 3H1 monoclonal antibody-murine anti-id. (1995) (0)
- Fate of 7-Interferon-activated Killer Blood Monocytes Adoptively Transferred into the Abdominal Cavity of Patients with Peritoneal Carcinomatosi* (2006) (0)
- Methods of Delaying Development of CEA-Associated Tumors Using Anti-Idiotype Antibody 3H1 (2017) (0)
- Interferon Therapy of Chronic Lymphocytic Leukemia and Viral Infections in Leukemia Patients (1988) (0)
- Early results of modified fludarabine, cyclophosphamide, and rituximab (mFCR) for patients with previously untreated advanced chronic lymphocytic leukemia (CLL). (2006) (0)
- Localization of 111 ln-and 125 l-labeled Monoclonal Antibody in Guinea Pigs Bearing Line 10 Hepatocarcinoma Tumors 1 (2006) (0)
- Advances in cancer: monoclonal antibody therapy of hematologic malignancies. (1987) (0)
- Anti-idiotype antibodies: novel therapeutic approach to cancer therapy. (1994) (0)
- Monoclonal anti-idiotype antibody 3h1 from mouse (1995) (0)
- Clinical a nd I mmune R esponses i n A dvanced M elanoma Patients I mmunized W ith a n A nti-Idiotype A ntibody Mimicking D isialogangliosi de G D2 (2000) (0)
- Treatment of Leukemia and Lymphoma with Biological Response Modifiers (1985) (0)
- CpG DNA augments dendritic cell-based therapy of colon cancer in transgenic mice (48.21) (2007) (0)
- Interferon therapy of lymphoproliferative disorders. (1986) (0)
- A Phase I/II Study of Reduced Dose FCR (FCR-lite) in Combination with Lenalidomide Followed By Lenalidomide Maintenance (FCR2) for Initial Therapy of CLL: Final Results and Long-Term Follow-up (2017) (0)
- Improved utilization of molecular imaging for response assessment in oncologic clinical trials by the University of Pittsburgh Imaging Response Assessment Teams (2007) (0)
- Human Alveolar Macrophages Express Ia (2005) (0)
- Aqueous Humor During Experimental Immunogenic Uveitis (0)
- New Therapeutic Options for Chronic Lymphocytic Leukemia (2007) (0)
- Growth inhibitory effect of supernatants obtained from peripheral mononuclear cells primed with anti-CD 3 Ab and r-interleukin 2 (1993) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Kenneth A. Foon?
Kenneth A. Foon is affiliated with the following schools: